

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person * <u>Cannon Kara</u>  (Last) (First) (Middle) <u>527 MADISON AVE</u>  (Street) <u>NEW YORK NY 10022</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>ENZO BIOCHEM INC [ ENZ ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) Other (specify below) Chief Operating Officer
	3. Date of Earliest Transaction (Month/Day/Year) <u>11/23/2022</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Stock Option (to acquire Common Stock)	\$1.97	11/23/2022		A		200,000		11/23/2023	11/23/2027	Common Stock	\$0	200,000 <sup>(1)</sup>	D	
Stock Option (to acquire Common Stock)	\$2.98							03/24/2023 <sup>(2)</sup>	03/24/2027	Common Stock		87,500	D	
Stock Option (to acquire Common Stock)	\$3.36							02/11/2023 <sup>(2)</sup>	02/11/2027	Common Stock		87,500	D	
Stock Option (to acquire Common Stock)	\$2.63							01/11/2022 <sup>(2)</sup>	01/11/2026	Common Stock		55,400	D	
Stock Option (to acquire Common Stock)	\$2.2							02/24/2021 <sup>(2)</sup>	02/24/2025	Common Stock		55,400	D	
Stock Option (to acquire Common Stock)	\$2.8							01/03/2020 <sup>(2)</sup>	01/03/2024	Common Stock		52,000	D	
Stock Option (to acquire Common Stock)	\$4.42							07/31/2019 <sup>(2)</sup>	07/30/2023	Common Stock		35,000	D	

**Explanation of Responses:**

- The Reporting Person was granted 200,000 stock options. The stock options have a five-year term and will vest, subject to the individual's continued employment with Enzo Biochem, Inc., in three equal annual installments, beginning on November 23, 2023.
- The stock options have a five-year term and will vest in three equal installments, one on the first anniversary of the grant date, the second on the second anniversary of the grant date and the third on the third anniversary of the grant date.

/s/ Kara Cannon

11/28/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.